Yale University

Licentia, Ltd.

Herantis Pharma Plc.

Herantis Pharma Oyj

Helsingin Yliopiston Rahastot

Hermo Pharma Ltd.

Juha Lauren

Mart Saarma

Raimo Tuominen

Paeivi Lindholm

Tonis Timmusk

Päivi Lindholm

Stephen M Strittmatter

Merja Voutilainen

David Gimbel

The invention provides methods of inhibiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrPc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinations, as well as methods of identifying molecules that could function as PrPantagonists.

Prion protein as a receptor for amyloid-&#x3b2; oligomers

The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.

MANF2 for treatment of Parkinson's disease

A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.

Treatment with a pharmaceutical composition comprising MANF2 necleic acid

Neurotrophic factor protein and uses thereof

Growing community of inventors

New Haven, CT, United States of America

Juha Lauren